RYE BROOK, NY, November 28, 2022 /PRNewswire/ — The Leukemia & Lymphoma Society is proud to announce that its strong financial health and continued accountability and transparency have earned LLS a four-star rating from Charity Navigator. This rating designates LLS as an official “Give with Confidence” charity, indicating that our organization uses its donations effectively based on the Charity Navigator criteria. Charity Navigator is the largest and most widely used independent charity evaluator in the United States. Since 2001, the organization has been an unbiased and trusted source of information for more than 11 million donors each year.
Charity Navigator four-star rating badge
Charity Navigator analyzes the performance of nonprofit organizations based on four key indicators, called beacons. Currently, nonprofits can earn scores for the Impact and Results, Accountability and Finances, Culture and Community, and Leadership and Adaptability tags.
“We are delighted to provide the Leukemia & Lymphoma Society (LLS) with third-party accreditation that validates its operational excellence,” said Michael Thatcher, President and CEO of Charity Navigator. “The four-star rating is the highest rating an organization can achieve. We look forward to seeing the good work that LLS is able to do in the years to come.”
“The Leukemia & Lymphoma Society’s four-star rating from Charity Navigator is a testament to our efficient and diligent stewardship of donor dollars that enables LLS to transform the treatment and care of blood cancer patients through investments in research and support services and in advocating for patient-centred policies,” said Louis J. De Gennaro, Ph.D., President and CEO of the Leukemia & Lymphoma Society (LLS). “We hope this achievement will introduce LLS to new supporters who will champion our mission to save lives and improve the quality of life for blood cancer patients and their families.”
LLS is proud of the results achieved through its significant investment in the mission. LLS has invested close to $1.5 billion in research since its founding in 1949. In the past five years alone, LLS has helped advance 75% of the nearly 100 blood cancer treatment options approved by the United States Food and Drug Administration. And LLS has increased its investment in pediatric blood cancer research and support to ensure that children with blood cancer not only survive their cancer, but thrive in life after treatment.
The impact of LLS is also evident in the work of its information specialists who handle approximately 20,000 patient inquiries a year, and the support of more than 200 volunteer advocacy leaders working on the ground in their capital cities. state and in washington d.c., and over 30,000 active online volunteers. The LLS remains steadfast in its work to find cures for blood cancers and ensure patients have access to lifesaving treatments.
The Leukemia & Lymphoma Society of Canada rating and other charitable giving information is available free of charge at charitynavigator.org.
About the Leukemia & Lymphoma Society (LLS)
The Leukemia and Lymphoma Society® (LLS) is the world leader in the fight against blood cancer. The mission of the LLS: To cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and to improve the quality of life of patients and their families. The LLS funds vital blood cancer research worldwide, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality coordinated care. , affordable.
Founded in 1949 and based in Rye Creek, NYLLS has regions across United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
LLS is one of Fast Company’s 2022 Brands That Matter. As the only cancer organization on the list, LLS stands out among brands around the world for its relevance, cultural impact, ingenuity and mission impact.
For more information, visit lls.org/lls-newsnetwork. Follow us on Facebook, Twitterand Instagram.
Please direct all media inquiries to [email protected].
SOURCE The Leukemia & Lymphoma Society (LLS)
